The goal of this clinical trial is to learn about the safety of Travoprost Ophthalmic Topical Cream and how well it works in lowering high intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT). A low dose, medium dose and high dose of Travoprost Ophthalmic Topical Cream will be compared to timolol maleate ophthalmic solution, 0.5% and to travoprost ophthalmic solution, 0.004%.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
250
travoprost ophthalmic topical cream low-dose once daily in the evening to both eyes
travoprost ophthalmic topical cream mid-dose once daily in the evening to both eyes
travoprost ophthalmic topical cream high-dose once daily in the evening to both eyes
Glaukos Clinical Study Site
Newport Beach, California, United States
RECRUITINGchange from baseline in mean diurnal IOP in the study eye
Day 29 mean diurnal IOP minus Baseline mean diurnal IOP in the study eye
Time frame: Day 29
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
timolol maleate ophthalmic solution, 0.5% twice daily (morning \& evening) to both eyes
travoprost ophthalmic solution, 0.004% once daily in the evening to both eyes